At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Anton Hagenbeek, MD, PhD, from the University of Amsterdam, Amsterdam, Netherlands, discusses immuno-oncology mechanisms and pathways that can be targeted by immunotherapies for patients with Hodgkin lymphoma or non-Hodgkin lymphoma. Highlighted approaches that are being explored include immune checkpoint inhibitors and brentuximab vedotin, an anti-CD30 antibody-drug conjugate.